





Article

New Antineoplastic Naphthohydroquinones Attached to Labdane and Rearranged Diterpene Skeletons

Ángela P. Hernández ^{1,2} , Pablo Chamorro ¹, M^a Lucena Rodríguez ¹, José M. Miguel del Corral ¹, Pablo A. García ¹ , Andrés Francesch ³, Arturo San Feliciano ^{1,4}  and M^a Ángeles Castro ^{1,*} 

- ¹ Departamento de Ciencias Farmacéuticas, Área de Química Farmacéutica, Facultad de Farmacia, CIETUS/IBSAL, University of Salamanca, Campus Miguel de Unamuno, 37007 Salamanca, Spain; angytahg@usal.es (Á.P.H.); chamorrosanchez@gmail.com (P.C.); mlucenarodriguez@gmail.com (M.L.R.); jmmcs@usal.es (J.M.M.d.C.); pabloagg@usal.es (P.A.G.); artsf@usal.es (A.S.F.)
- ² Department of Medicine and General Cytometry Service-Nucleus, CIBERONC CB16/12/00400, Cancer Research Centre (IBMCC/CSIC/USAL/IBSAL), 37007 Salamanca, Spain
- ³ PharmaMar S.A., Avda de los Reyes, 1, 28770 Colmenar Viejo, Spain; afrancesch@pharmamar.com
- ⁴ Programa de Pós-Graduação em Ciências Farmacéuticas, Universidade do Vale do Itajaí, UNIVALI, 88302-202 Itajaí, SC, Brazil
- * Correspondence: macg@usal.es; Tel.: +34-923294500 (ext. 1824)



Citation: Hernández, Á.P.; Chamorro, P.; Rodríguez, M.L.; Miguel del Corral, J.M.; García, P.A.; Francesch, A.; San Feliciano, A.; Castro, M.Á. New Antineoplastic Naphthohydroquinones Attached to Labdane and Rearranged Diterpene Skeletons. *Molecules* **2021**, *26*, 474. <https://doi.org/10.3390/molecules26020474>

Academic Editors: Maria Emília de Sousa, Katalin Prokai-Tatrai, Paula A. C. Gomes, Stefania Galdiero, Sandra Gemma, Mariana Spetea and Anne Roivainen

Received: 29 December 2020

Accepted: 15 January 2021

Published: 18 January 2021

Publisher's Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.



Copyright: © 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>).

Abstract: Terpenylquinones are mixed biogenesis primary or secondary metabolites widespread in Nature with many biological activities, including the antineoplastic cytotoxicity, that have inspired this work. Here, we present a cytotoxic structure-activity relationship of several diterpenylhydroquinone (DTHQ) derivatives, obtained from the natural labdane diterpenoid myrceocommunic acid used as starting material. Different structural modifications, that changed the functionality and stereochemistry of the decalin, have been implemented on the bicyclic core through epoxidation, ozonolysis or decarboxylation, and through induction of biomimetic breaks and rearrangements of the diterpene skeleton. All the isomers generated were completely characterized by spectroscopic procedures. The resulting compounds have been tested in vitro on cultured cancer cells, showing their relevant antineoplastic cytotoxicity, with GI₅₀ values in the μM and sub-μM range. The rearranged compound **8** showed the best cytotoxic results, with GI₅₀ at the submicromolar range, retaining the cytotoxicity level of the parent compounds. In this report, the versatility of the labdane skeleton for chemical transformation and the interest to continue using structural modifications to obtain new bioactive compounds are demonstrated.

Keywords: terpenylquinone; rearranged diterpenes; labdane; halimane; cytotoxicity

1. Introduction

Terpenyl-quinones/hydroquinones (TQs/THQs) are mixed biogenesis primary or secondary metabolites widespread in Nature. Examples of primary metabolites are vitamin K, tocopherols, ubiquinones or plastoquinones that play important roles in the electron transport chain or in photosynthesis [1]. As secondary metabolites, TQs/THQs have been isolated from different sources, particularly of marine origin such as avarol or avarone (Figure 1), and they often have a wide variety of biological activities, mainly antineoplastic and antioxidant properties, that have been related to their involvement in redox cycling and/or Michael-1,4-addition reactions [2,3].

Our research group has been involved in the design, synthesis and biological evaluation of several series of TQs/THQs, derived either from the monoterpene β-myrcene or the diterpenoid myrceocommunic acid, giving rise to two series of compounds named monoterpenylquinones (MTQs/MTHQs) and diterpenylquinones (DTQs/DTHQs) (Figure 1). We have prepared a large number of derivatives with variations in sizes and functionalities of both the quinone and the terpenoid moieties. Very interesting antineoplastic compounds were obtained from β-myrcene [4–10] and myrceocommunic acid [11–14], being

the DTQs/DTHQs slightly more potent than the MTQs/MTHQs. About the quinone size, 1,4-naphthoquinone (NQ) and 1,4-anthracenequinone (AQ) analogues were more potent than the corresponding benzoquinones (BQs) and 9,10-AQs, the common moiety in clinically used anticancer drugs, without significant differences between the quinone functions and the corresponding acetylated hydroquinones. Particularly interesting have been the results of several DTHQ-cyclolignan hybrids against the osteosarcoma cell line MG-63, which is a very aggressive type of cancer [14].




Figure 1. Structures of representative terpenylquinones (TQ) and terpenylhydroquinones (THQ). (A) Examples of natural TQs and THQs. (B) General structure of monoterpenylquinones/hydroquinones (MTQ/MTHQs) derived from β -myrcene. (C) General structure of diterpenylquinones/hydroquinones (DTQ/DTHQs) derived from myrceocommunic acid.

In addition to the cytotoxicity assays, several of our TQs/THQs were evaluated as antifungal [10,15], antiviral [10,16] and anti-leishmanial [17], attaining promising results against yeasts, filamentous fungi and *Leishmania infantum*.


In our previous research, many MTQs/MTHQs have been obtained by transformation of the side chain derived from the monoterpene [5,6,9,10], however only a few examples dealt with modifications of the diterpenoid core, always keeping the labdane type decalin [11,12]. Now, we describe further chemical transformations performed at this decalin moiety in the DTHQ series, either at the A or B decalin rings, including isomerizations, decarboxylations or rearrangements, leading to derivatives with modified diterpenoid skeletons, which have been evaluated against four tumor cell lines, representative of common and multi-drug resistant cancer types affecting lung, colon, breast and skin, to analyze the influence of those modifications on their cytotoxicity.

2. Results and Discussion

2.1. Chemistry

Continuing with our research on the field of terpenylquinones and considering the previous interesting results, we decided to enlarge the structural diversity of our DTHQ derivatives by chemical transformations on the decalin core, taking advantage of the functional groups present on it, i.e., the double bond around C-8 and the carboxylic group at C-4, making use of reactions such as epoxidation, ozonolysis and decarboxylation, which were applied to the previously reported DTHQs 1–4.

The starting DTHQs 1 and 2 were prepared through a Diels-Alder cycloaddition between myrceocommunic acid or methyl myrceocommunicate and *p*-benzoquinone (Scheme 1), following the procedure previously described by us [11,12]. Isomerization of the $\Delta^{8(17)}$ double bond, in both 1 and 2 to the more stable endocyclic and tetrasubstituted Δ^8 double bond, was achieved by treatment with aq 57% HI at 80 °C to yield the DTHQs 3 and 4 [13].




Scheme 1. Synthesis of the starting DTHQs 1–4.

2.1.1. Epoxidation and Rearrangement Reactions


It is well known that the Lewis acid-catalyzed rearrangement of epoxides is an efficient tool to obtain new compounds through carbocation rearrangements [18]. In fact, in our previous work [11], the epoxidation of the $\Delta^{8(17)}$ double bond, followed by rearrangement promoted by $\text{BF}_3 \cdot \text{Et}_2\text{O}$, gave the corresponding aldehyde at C-17, with improved cytotoxicity respecting DTHQ 2. Here in this work, in order to increase the structural diversity of our DTHQs, we explore the rearrangement products of the endocyclic Δ^8 double bond epoxidation.

Treatment of 4 with MCPBA afforded a mixture of the two possible epoxides 5 and 6 in a 2:1 ratio. Both isomers were separated by column chromatography, characterized through their NMR spectra and treated separately with $\text{BF}_3 \cdot \text{Et}_2\text{O}$ (Scheme 2).

Reaction of the β -epoxide 5 with the Lewis acid at -78 °C gave compounds 7, 8 and the isomers 9a and 9b. The ^1H - and ^{13}C -NMR spectra of DTHQ 7 indicated the presence of the exocyclic double bond at C-8, similar to that present in DTHQs 1 and 2, whereas the spectrum of 7 didn't have the characteristic signal of the axial methyl group of a labdane type decalin. In fact, such signal moved from around 0.5 ppm to 1.19 ppm; this fact, together with the ^{13}C -NMR data and the molecular formula $\text{C}_{31}\text{H}_{36}\text{O}_6$ by HRMS, indicated us that the labdane decalin was rearranged to an halimane type decalin [19] with a tetrasubstituted $\Delta^{5(10)}$ double bond. The configuration at C-9 was deduced from the proposed epoxide rearrangement mechanism, probably via an unconcerted mechanism [19], that involved 1,2-shift of the axial methyl group at C-10 as illustrated by pathway "I" in Scheme 3.



Scheme 2. Epoxidation of 4 and rearrangement of epoxides 5 and 6 promoted by $\text{BF}_3 \cdot \text{Et}_2\text{O}$.




Scheme 3. Proposed mechanism for the epoxide 5 rearrangement leading to compounds 7–9.

The ^1H and ^{13}C -NMR spectra of DTHQ 8 showed signals for a ketone function and three methyl groups on aliphatic quaternary carbons. Several spectroscopic experiments (NOE, HMBC and HMQC and HRMS data) confirmed the contraction of the ring by migration of the chain following the pathway "II" shown in Scheme 3.

Compounds 9a and 9b showed to be regioisomers that practically coeluted in the CC, and only a small amount of 9a was purified. They had a tertiary hydroxyl group and very similar spectroscopic properties, being the main difference in the ^1H -NMR spectra, the presence or absence of an olefinic proton signal at 5.52 ppm. NOE, HMBC and HMQC experiments performed on 9a allowed to locate the double bond at the $\Delta^{1(10)}$ position and to assign the *S* configuration for C-8; consequently, the double bond in 9b should be placed in position $\Delta^{5(10)}$ and this compound would be the precursor of 7 through loss of a water molecule (Scheme 3).

Rearrangement of the α -epoxide 6 in the same conditions yielded a reaction product from which the ketone 10 and the alcohol 11 were isolated by CC (Scheme 2). The NMR data of 10 indicated the presence of a ketone (210.0 ppm) and two methyl groups on a double bond (1.62 and 1.69 ppm). HRMS, HMBC and HMQC experiments corroborated the opening of the B-ring of the decalin, and its degradation can be explained from the proposed rearrangement mechanism shown in Scheme 4. The *Z* configuration for the

double bond was proposed on the basis of this mechanism and literature data for the ^{13}C NMR chemical shift of methyl groups on double bonds [20].




Scheme 4. Proposed mechanism for the epoxide **6** rearrangement leading to ketoester **10** and hydroxyester **11**.

Compound **11** had spectra data very similar to those of compound **9a**, with simple differences in the chemical shifts of the C-17 and C-20 methyl groups, thus indicating that **11** should be the C-8 epimer of **9a**.

2.1.2. Ozonolysis

Ozonolysis is a well-known reaction for oxidative cleavage of carbon-carbon double bonds to get carbonyl compounds under reductive or oxidative conditions [21]. It has been widely used for structure elucidation of organic compounds, but also to get fragments with carbonyl groups. Interestingly, if the double bond is within a ring, a chain containing two carbonyls is obtained.

In the work described here, DTHQs **1** and **2** have an exocyclic double bond and its ozonolysis under reductive work-up conditions gave respectively the ketones **12** and **13**, both having a 17-norlabdane decalin core (Scheme 5). However, DTHQ **4** has an endocyclic tetrasubstituted double bond and its ozonolysis afforded the 8,9-secolabdane diketone **14** and the epoxide **6** in a 1:1.5 ratio (Scheme 5). The formation of epoxides is frequent during ozonolysis of sterically hindered double bonds [22] as it happens in the case of **4**.




Scheme 5. Ozonolysis and further reactions of DTHQs **1**, **2** and **4**.

Diketone **14** was submitted to further intramolecular aldolic condensation in the presence of DBU giving rise to the rearranged labdane derivative **15** (Scheme 5). Under basic conditions, a partial saponification of the aromatic acetates was observed, so the reaction product was acetylated to restore the naphthohydroquinone diacetate moiety of the starting DTHQs. Both the secodecalin and the rearranged labdane derivative were characterized by spectroscopic comparison with the natural products chapecoderins A and B, which have the same labdane skeletons without the carboxylic function at C-19 [23].

2.1.3. Decarboxylation Reactions


The last type of transformations performed on the DTHQs take advantage of the presence of the carboxylic group, which allows to get derivatives modified at the A-ring of the decalin. We obtained several 19-nor-DTHQs from **1** and **3** by decarboxylation with lead tetraacetate (LTA) [24]. Thus, the oxidative decarboxylation of **1** with LTA and cupric acetate in toluene-pyridine gave a 5:7:10 mixture (as deduced from the C-20 methyl signal the $^1\text{H-NMR}$ spectrum) of the three unsaturated derivatives **16a–c** respectively, and the triacetate **17** [25] (Scheme 6). When this reaction product was treated with $\text{BF}_3 \cdot \text{Et}_2\text{O}$, the triacetate was transformed into the olefins **16a–c**. The three isomers **16a–c** were practically inseparable by CC, even using silica gel impregnated with silver nitrate, and only a small amount of the **16a**, which has two exocyclic methylenes, was separated. Consequently, the mixture **16a–c** was treated with HI to attempt the isomerization to the more stable Δ^4 and Δ^8 endocyclic double bonds. However, the isomerization was not complete and a mixture of **18b** and **18c** was obtained (Scheme 6). To force the isomerization towards **18c**, the mixture **18b,c** was treated with iodine in toluene for longer time, however, a complex reaction product was obtained from which the rearranged aromatic derivative **19** was separated and characterized (Scheme 6). The isomer **18c** was also obtained after treatment of DTHQ **3** with LTA followed by reaction with iodine for 3 h (Scheme 6).



Scheme 6. Decarboxylations and further reactions of DTHQs **1**, **3** and **12**.

The oxidative decarboxylation was also applied to DTHQ **12** to afford the ketoacetate **20** and the isomers **21a–c** (Scheme 3). When the mixture **21a–c** was treated with iodine, the isomer **21c**, having the most stable tetrasubstituted double bond, was isolated and characterized.

The structure of compound **19** was deduced from the analysis of its spectroscopic properties. Among the most characteristic signals in its $^1\text{H-NMR}$ spectrum, those corresponding to three methyl groups stood out, one doublet at 1.30 ppm and two singlets at 2.35 and 2.23 ppm, the latter assignable to methyls attached to an aromatic ring. Additional spectroscopic experiments ($^{13}\text{C-NMR}$, HRMS, NOE, HMBC and HMQC) confirmed the structure of **19**, whose formation can be explained by the proposed mechanism shown in Scheme 7, in which the observed NOEs for **19** are shown with blue arrows, although the absolute configuration at C-4 could not be determined. Similar rearrangements towards B-ring aromatization have also been described for other natural labdanes [26].



Scheme 7. Proposed mechanism for the formation of compound **19**. The blue arrows represent the experimentally observed NOEs.

2.2. Biological Evaluation

Cell killing ability of the synthesized DTHQ derivatives was conducted against a panel of three human tumor cell lines with high incidence in the population [27], including non-small cell lung carcinoma (A-549), colon adenocarcinoma (HT-29), and multi-drug-resistant breast carcinoma (MDA-MB-231). The *in vitro* antiproliferative activity was assessed using the colorimetric SRB (sulforhodamine B) method [28] and the common anticancer naphthacenequinone drug doxorubicin was included in the assays as reference. The GI_{50} (μM) values (concentration that causes 50% growth inhibition), for all the tested compounds are shown in Table 1. Additionally, compounds **1**, **2**, **8**, and **21a** were also assayed on malignant skin melanoma SK-MEL-28 cells with GI_{50} values of 0.24, 0.12, 0.54 and 1.66 μM respectively.

From these results, it can be stated that the compounds assayed were fairly cytotoxic for neoplastic cells. Indeed, some of them showed GI_{50} values similar to those of doxorubicin. In general, the presence of oxygenated functions, the opening, contraction or rearrangement of the decalin moiety gave compounds that kept or slightly decreased the potency of the lead compounds **1** and **2**.

Table 1. Antineoplastic cytotoxicity (GI₅₀ values in μ M) of DTHQs 1–21 against A-549 (lung), HT-29 (colorectal) and MB-231 (breast) tumor cell lines (nt: not tested).

Compound	A-549	HT-29	MB-231
1	0.24	0.24	nt
2	0.12	0.50	nt
3	0.20	0.20	nt
4	0.24	0.24	nt
5	0.96	0.96	3.25
6	0.24	0.24	1.21
7	5.00	5.00	nt
8	0.19	0.19	nt
9a	3.25	4.21	3.25
10	4.80	4.80	1.26
11	3.64	3.64	2.68
12	10.10	10.10	4.25
13	4.90	4.90	nt
14	3.01	>5.41	nt
15	2.97	2.97	1.54
16a–c	2.02	3.82	2.07
16a	2.24	4.25	2.06
17	0.83	0.86	1.06
18a	0.22	0.22	nt
18c	0.22	0.22	nt
19	1.42	2.47	1.78
20	0.86	0.86	1.06
21a	3.12	2.90	2.45
21c	5.00	5.00	nt
Doxorubicin	0.31	0.26	0.16

There were no differences in potency between compounds with exocyclic or endocyclic double bond in the B-ring of the decalin core (compounds 1–4). The presence of a ketone in such ring led to less potent compounds (12, 13 and 21 vs. 1 and 2), while DTHQ 12, with a free carboxylic group, was the less potent compound of the series on the three cell lines. Interestingly, the α -epoxide 6 was four times more potent than the β -epoxide 5, what is in accordance with previous results obtained with the $\Delta^{8(17)}$ epoxides [11]. Those analogues with a halimane type decalin and a hydroxyl group at C-8 (9 and 11), were less potent than their precursors, though keeping their cytotoxicity values in the micromolar range. The same happened with DTHQs 10 and 14, which lacked the decalin B-ring. Several differences were observed for DTHQs 8 and 15, which had an indane system, being 8 as potent as its precursors, while 15 was fairly less potent. Such a remarkable difference, of more than one order of magnitude, would be accounted for by an intramolecular hydrogen bonding between the carbonyl and the hydroxyl group attached to the cyclopentane ring in 15, which would prevent potential interactions with hypothetical targets, unlike the free ketone in 8. The presence of the ketone out of the bicyclic core in 8 may also have a positive impact on activity, since other decalin compounds with ketone groups located on the ring, such as 12, 13 or 21, resulted less potent than the indanyl ketone 8.

The decarboxylated analogues were, in general, less potent than the parent compounds; however, DTHQ 18 had the same GI₅₀ value than its precursor without differences between the a–c isomers, and DTHQs 17 and 20, with an acetoxy group at C-4, retained the submicromolar cytotoxicity.

Finally, in terms of cytotoxic potency, these results indicated that a varied range of functionalization in the B-ring was tolerated and that the ester function in the A-ring seemed to be important for the antineoplastic cytotoxicity.

3. Materials and Methods

3.1. Chemistry

NMR experiments were recorded on a Bruker WP 200 SY (Bruker GmbH, Karlsruhe, Germany) (200 and 50.3 MHz for ^1H and ^{13}C) or Bruker Avance 400DRX (Bruker GmbH, Karlsruhe, Germany) (400 and 100 MHz) spectrometers in CDCl_3 using TMS as internal reference. Chemical shift (δ) values are expressed in ppm followed by multiplicity and coupling constants (J) in Hz. Optical rotations were recorded on a Perkin-Elmer 241 polarimeter (Perkin-Elmer GmbH, Uberlingen, Germany) in CHCl_3 solution. UV spectra were obtained on a Hitachi 100–60 spectrophotometer (Hitachi High-Technologies Corporation, Tokyo, Japan) in ethanol solution, and λ_{max} are given in nm. IR spectra were obtained on a Nicolet Impact 410 spectrophotometer (Nicolet Instrument Corporation, Madison, WI, USA) in NaCl film. HRMS were run in a VG TS-250 spectrometer (VG Instruments, Manchester, UK) working at 70 eV, using electrospray ionization (ESI) or fast atom bombardment (FAB). Elemental analysis (C, H, N) were obtained with a PERKIN-ELMER 2400 CHN (Perkin-Elmer GmbH, Uberlingen, Germany). Solvents and reagents were purified by standard procedures as necessary. Column chromatography (CC) purifications were performed using silica gel 60 (40–63 mm, 230–400 mesh, Merck) and TLC was carried out on silica gel 60 F₂₄₅ (Merck, 0.25 mm thick). NMR assignments are included in the Supplementary material: Tables S1–S20.

Diterpenyl-naphthohydroquinone diacetates **1**, **2** and **4** were obtained by means of previously described procedures [11,12]. Other compounds were prepared as follows.

DTHQ 3. To a 10^{-2} M solution of **1** (185 mg, 0.38 mmol) in toluene (37 mL) aq HI 57% (0.86 mL) was added. The mixture was stirred at 80 °C for 10 min. Then, ethyl acetate was added and the organic layer was washed with aq satd NaHCO_3 and brine, dried over Na_2SO_4 , filtered and evaporated off yielding the Δ^8 product **3** (182 mg, 0.37 mmol, 98%): IR cm^{-1} (film): 2930, 1765, 1690, 1450, 1365, 1200, 1180, 1050, 820, 735. Anal. Calcd. for $\text{C}_{30}\text{H}_{36}\text{O}_6$: C, 73.15; H, 7.37. Found C, 73.12%; H, 7.36%. RMN ^1H : Table 2. RMN ^{13}C : Table 3.

Table 2. ^1H -NMR data for compounds **3**, **5**–**13** (δ ppm (J in Hz)).

H	3 *	5 **	6 **	7 *	8 **	9a **	10 *	11 **	12 *	13 *
1						5.52 <i>m</i>		5.61 <i>m</i>		
14	7.42 <i>dd</i> (8.8, 1.8)	7.37 <i>dd</i> (8.6, 1.6)	7.35 <i>dd</i> (8.6, 1.3)	7.32 <i>dd</i> (8.8, 1.8)	7.38 <i>d</i> (8.6)	7.39 <i>dd</i> (8.8, 1.6)	7.42 <i>dd</i> (8.8, 1.3)	7.39 <i>dd</i> (8.6, 1.6)	7.38 <i>dd</i> (8.8, 1.5)	7.34 <i>d</i> (8.8)
15	7.77 <i>d</i> (8.8)	7.77 <i>d</i> (8.6)	7.77 <i>d</i> (8.6)	7.75 <i>d</i> (8.8)	7.77 <i>d</i> (8.6)	7.78 <i>d</i> (8.8)	7.78 <i>d</i> (8.8)	7.80 <i>d</i> (8.6)	7.78 <i>d</i> (8.8)	7.75 <i>d</i> (8.8)
16	7.59 <i>bs</i>	7.57 <i>bs</i>	7.57 <i>bs</i>	7.55 <i>bs</i>	7.63 <i>s</i>	7.59 <i>bs</i>	7.64 <i>bs</i>	7.59 <i>bs</i>	7.51 <i>bs</i>	7.50 <i>bs</i>
17	1.70 <i>s</i>	1.32 <i>s</i>	1.38 <i>s</i>	5.10 <i>bs</i> 4.95 <i>bs</i>	1.17 <i>s</i>	1.13 <i>s</i>	1.62 <i>s</i>	1.11 <i>s</i>	-	-
18	1.29 <i>s</i>	1.17 <i>s</i>	1.16 <i>s</i>	1.17 <i>s</i>	1.15 <i>s</i>	1.37 <i>s</i>	1.28 <i>s</i>	1.40 <i>s</i>	1.27 <i>s</i>	1.16 <i>s</i>
20	0.91 <i>s</i>	0.86 <i>s</i>	0.93 <i>s</i>	0.86 <i>s</i>	0.65 <i>s</i>	1.15 <i>s</i>	1.69 <i>s</i>	1.19 <i>s</i>	0.63 <i>s</i>	0.50 <i>s</i>
2'	7.21 <i>d</i> (8.2)	7.21 <i>d</i> (8.2)	7.22 <i>d</i> (8.2)	7.21 <i>d</i> (8.2)	7.21 <i>d</i> (8.2)	7.16 <i>d</i> (8.4)	7.21 <i>d</i> (8.2)	7.23 <i>d</i> (8.2)	7.21 <i>d</i> (8.0)	7.16 <i>d</i> (8.0)
3'	7.16 <i>d</i> (8.2)	7.16 <i>d</i> (8.2)	7.16 <i>d</i> (8.2)	7.16 <i>d</i> (8.2)	7.17 <i>d</i> (8.2)	7.21 <i>d</i> (8.4)	7.15 <i>d</i> (8.2)	7.18 <i>d</i> (8.2)	7.16 <i>d</i> (8.0)	7.11 <i>d</i> (8.0)
2 x OAc	2.44 <i>s</i> , 2.46 <i>s</i>	2.44 <i>s</i> , 2.46 <i>s</i>	2.45 <i>s</i> , 2.47 <i>s</i>	2.44 <i>s</i> , 2.46 <i>s</i>	2.44 <i>s</i> , 2.48 <i>s</i>	2.45 <i>s</i> , 2.46 <i>s</i>	2.45 <i>s</i> , 2.50 <i>s</i>	2.45 <i>s</i> , 2.47 <i>s</i>	2.45 <i>s</i> , 2.46 <i>s</i>	2.36 <i>s</i> , 2.38 <i>s</i>
19-OCH₃	-	3.63 <i>s</i>	3.63 <i>s</i>	3.63 <i>s</i>	3.63 <i>s</i>	3.70 <i>s</i>	3.61 <i>s</i>	3.72 <i>s</i>	-	3.54 <i>s</i>

* 200 MHz; ** 400 MHz.

Table 3. ¹³C-NMR data for compounds 3,5–13 (δ ppm).

C	3 *	5 **	6 **	7 *	8 **	9a **	10 *	11 **	12 *	13 *
1	37.7	34.2	37.4	40.8	35.1	120.5	39.3	122.4	39.1	38.9
2	19.5	18.8	18.6	19.3	20.3	22.3	21.9	22.4 #	19.5	19.4
3	37.0	37.4	37.4	35.3	36.8	24.7	33.8	24.3	37.4	37.5
4	43.7	43.5	43.9	47.9 #	44.0	44.4	50.5	44.4	44.1	43.9
5	53.4	45.6	54.7	134.6	52.9	41.4	58.0	41.4	54.6	54.3
6	29.6	18.9	20.1	26.4	23.1	27.5	25.0	27.4 #	25.5	25.4
7	30.3	30.4	33.3	34.2	33.2	37.3	33.3	35.4	43.0	42.8
8	127.5	63.1	64.8	151.9	60.6	75.9	128.0	75.0	211.9	211.4
9	138.5	70.9	70.9	37.2 #	216.1	48.5	128.7	49.0	61.5	61.3
10	39.8	39.1	38.9	128.6	47.0	140.9	210.0	140.8	43.6	43.2
11	20.6	29.0	33.3	23.9	43.2	35.7	36.2	38.0	23.1	23.0
12	34.2	33.2	35.8	31.1	30.4	30.9	35.4	31.4	34.8	34.6
13	141.9	141.6	141.5	142.4	140.5	142.3	141.5	141.8	141.2	140.9
14	128.2	128.2	128.0	128.4	128.4	128.5	128.6	128.2	128.4	128.2
15	121.6	121.7	121.8	121.6	121.8	121.7	121.5	121.9	121.7	121.5
16	119.4	119.6	119.5	119.9	120.4	119.8	119.9	119.8	120.1	119.8
17	19.8	22.2	21.0	106.4	20.1	24.0 #	18.3	17.2	-	-
18	28.5	28.7	28.3	26.2	28.3	22.3	24.3	22.4	28.8	28.4
19	184.4	178.0	177.8	177.7	178.1	177.7	175.6	177.5	182.9	176.7
20	17.9	15.5	14.5	23.4	14.8	16.8 #	18.6	22.7	13.3	12.9
1'	143.8	143.9	143.9	143.8	143.9	143.8	144.0	143.9	143.9	143.7
2'	117.6	116.7	116.8	116.6	116.9	116.7	116.6	116.8	116.8	117.5
3'	116.6	117.7	117.8	117.7	117.8	117.7	117.6	117.8	117.7	116.6
4'	144.2	144.3	144.3	144.3	144.3	144.3	144.3	144.3	144.3	144.1
5'	126.1	126.1	126.1	126.0	126.2	125.2	126.1	126.1	126.2	125.9
6'	127.7	127.8	127.8	127.8	127.7	127.8	127.8	127.8	127.7	127.5
OAc (2xCO)	169.4	169.3	169.4	169.3	169.3 169.2	169.4	169.5 169.3	169.3	169.3	169.0
OAc (2xCH ₃)	20.9	20.9 21.0	21.0	21.0	21.0	21.0	21.0	20.9	20.9	20.7
19-OCH ₃	-	51.1	51.2	51.9	51.1	51.5	51.7	51.5	-	51.0

* 50 MHz; ** 100 MHz. # Exchangeable signals within each compound.

DTHQ epoxides **5** and **6**. Compound **4** (178 mg, 0.35 mmol) was dissolved in dichloromethane and MCPBA (485 mg, 1.55 mmol) and NaHCO₃ (528 mg) were added. The mixture was kept at room temperature for 3 h. Then dichloromethane was added, followed by 10% aqueous Na₂S₂O₃ until the oxidant was eliminated. The organic layer was washed with brine and dried over anhydrous Na₂SO₄, and the solvent evaporated off. The reaction product was purified by CC (CHCl₃/EtOAc 9:1) to obtain: 65 mg (35%) of epoxide **5**, 42 mg (23%) of mixture of **5** and **6** and 28 mg (15%) of epoxide **6**. Compound **5**: [α]_D²² = +50.9 (c, 0.97%); IR cm⁻¹ (film): 2945, 1764, 1717, 1462, 1433, 1366, 1262, 1203, 1182, 1053, 891, 825; UV λ_{max} (ε): 240 (12300), 287 (5500). HRMS-FAB: calcd for C₃₁H₃₉O₇ [M + H]⁺ 523.2696; found 523.2742 *m/z*. RMN ¹H: Table 2. RMN ¹³C: Table 3. Compound **6**: [α]_D²² = +25.1 (c, 1.0%); IR cm⁻¹ (film): 2920, 2850, 1765, 1720, 1610, 1465, 1365, 1200, 1180, 1050, 890, 825, 735; HRMS-FAB: calcd for C₃₁H₃₉O₇ [M + H]⁺ 523.2696 u; found 523.2698 *m/z*; RMN ¹H: Table 2. RMN ¹³C: Table 3.

Rearranged DTHQs **7**, **8** and **9**. To a solution of epoxide **5** (62 mg, 0.12 mmol) in dry dichloromethane, cooled at −78 °C, BF₃·Et₂O (55 μL, 0.43 mmol) was added under inert atmosphere. The mixture was stirred at this temperature for 3 h. Then the solvent was removed, and the crude dissolved in EtOAc, washed with brine, dried over Na₂SO₄, and the solvent evaporated off. The reaction crude was chromatographed to yield: 6 mg (9%, eluent: Hex/EtOAc, 9:1) of **7**, 24 mg (38%, eluent: Hex/EtOAc, 9:1) of **8**, 7 mg (11%, eluent: Hex/EtOAc, 7:3) of **9a** and 17 mg (27%, eluent: Hex/EtOAc, 7:3) of **9a,b**. Compound **7**: IR cm⁻¹ (film): 2935, 1765, 1725, 1610, 1450, 1365, 1200, 1050, 1010, 895, 825, 735; HRMS-FAB: calcd for C₃₁H₃₇O₆ [M + H]⁺ 505.2590; found 505.2623 *m/z*. RMN ¹H: Table 2. RMN ¹³C:

Table 3. Compound **8**: $[\alpha]_D^{22} = +19.7$ (c, 0.97%); IR cm^{-1} (film): 2495, 1765, 1720, 1625, 1610, 1450, 1365, 1200, 1050, 1005, 895, 825, 735; HRMS-FAB: calcd for $\text{C}_{31}\text{H}_{39}\text{O}_7$ $[\text{M}+\text{H}]^+$ 523.2696; found 523.2700 m/z . RMN ^1H : Table 2. RMN ^{13}C : Table 3. HMQC and HMBC experiments: Table S1. Compound **9a**: IR cm^{-1} (film): 3515, 2935, 1765, 1610, 1450, 1365, 1265, 1200, 1120, 1010, 915, 820, 730; HRMS-FAB: calcd for $\text{C}_{31}\text{H}_{37}\text{O}_6$ $[\text{M}+\text{H}]^+$ 505.2590; found 505.2623 m/z . RMN ^1H : Table 2. RMN ^{13}C : Table 3. HMQC and HMBC experiments: Table S2.

Rearranged DTHQs **10** and **11**. To a solution of epoxide **6** (89 mg, 0.17 mmol) in dry dichloromethane, cooled at -78°C , $\text{BF}_3\text{-Et}_2\text{O}$ (78 μL , 0.61 mmol) was added under inert atmosphere. The mixture was stirred at this temperature for 3 h. Then the solvent was removed, and the crude dissolved in EtOAc, washed with brine, dried over Na_2SO_4 , and the solvent evaporated off. The reaction crude was chromatographed to yield: 25 mg (28%, eluent: Hex/EtOAc, 7:3) of **10** and 29 mg (32%, eluent: Hex/EtOAc, 6:4) of **11**. Compound **10**: $[\alpha]_D^{22} = +2.8$ (c, 0.65%); IR cm^{-1} (film): 2948, 1765, 1727, 1608, 1462, 1433, 1366, 1020, 1182, 1053, 897, 825, 735. HRMS-FAB: calcd for $\text{C}_{31}\text{H}_{39}\text{O}_7$ $[\text{M} + \text{H}]^+$: 523.2696; found 523.2674 m/z . Anal. Calcd. for $\text{C}_{31}\text{H}_{38}\text{O}_7$: C, 71.24; H, 7.33. Found C, 71.19%; H, 6.90%. RMN ^1H : Table 2. RMN ^{13}C : Table 3. HMQC and HMBC experiments: Table S3. Compound **11**: $[\alpha]_D^{22} = -62.4$ (c, 0.65%); IR cm^{-1} (film): 3536, 2936, 1765, 1728, 1609, 1462, 1433, 1365, 1203, 1182, 1054, 1016, 939, 899, 736. UV λ_{max} (ϵ): 240 (12600), 286 (4600). HRMS-ESI: calcd for $\text{C}_{31}\text{H}_{38}\text{O}_7\text{Na}$ $[\text{M} + \text{Na}]^+$: 545.2509; found 545.2528 m/z . RMN ^1H : Table 2. RMN ^{13}C : Table 3. HMQC and HMBC experiment: Table S4.

General procedure for ozonolysis. nor-DTHQ **12**. A solution of compound **1** (340 g, 0.69 mmol) in dry CH_2Cl_2 (6 mL) was cooled to -78°C , and ozone was bubbled (30 nL/h, 0.6 amperes) through the mixture for 10 min. Then the reaction mixture was purged with oxygen for 10 min and argon for additional 5 min to remove the ozone excess. Then, dimethyl sulfide (1.5 mL, 19 mmol) was added to the mixture and stirred for 6 h. The solvent was distilled off, the residue was dissolved in EtOAc and washed with brine. The organic layer was dried over anhydrous Na_2SO_4 and evaporated off to give a reaction product that was purified by CC on silica-gel (eluent: Hex/EtOAc, 7:3) to yield **12** (227 mg, 66%). IR cm^{-1} (film): 2950, 1765, 1705, 1695, 1610, 1450, 1365, 1200, 1050, 1010, 915, 895, 735. RMN ^1H : Table 2. RMN ^{13}C : Table 3. HRMS-FAB: calcd for $\text{C}_{29}\text{H}_{35}\text{O}_7$ $[\text{M} + \text{H}]^+$: 495.2383; found 495.2377.

nor-DTHQ **13**. Starting from **2** (220 mg, 0.44 mmol) and following the above procedure for ozonolysis, the reaction product yielded **13** (212 mg, 96%). IR cm^{-1} (film): 2935, 1765, 1720, 1710, 1610, 1450, 1365, 1200, 1050, 825, 735. HRMS-FAB: calcd for $\text{C}_{30}\text{H}_{37}\text{O}_7$ $[\text{M} + \text{H}]^+$: 509.2539; found 509.2602 m/z . RMN ^1H : Table 2. RMN ^{13}C : Table 3.

seco-DTHQ **14**. Starting from **4** (171 mg, 0.34 mmol) and following the above procedure for ozonolysis, the reaction product was chromatographed to yield **6** (74 mg, 40%, eluent: Hex/EtOAc, 7:3) and **14** (49 mg, 27%, eluent: Hex/EtOAc, 8:3). $[\alpha]_D^{22} = +19.0$ (c, 0.97%); IR cm^{-1} (film): 2945, 1764, 1717, 1462, 1433, 1366, 1262, 1203, 1182, 1053, 891, 825. UV λ_{max} (ϵ): 240 (12300), 289 (4500). HRMS-FAB: calcd for $\text{C}_{31}\text{H}_{39}\text{O}_8$ $[\text{M} + \text{H}]^+$: 539.2645; found 539.2618 m/z . RMN ^1H : Table 4. RMN ^{13}C : Table 5. HMQC and HMBC experiments: Table S5.

Rearranged DTHQ **15**. To a stirred solution of **14** (59 mg, 0.11 mmol) in dry toluene (3 mL) was added 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU) (27 μL , 0.16 mmol). The reaction mixture was stirred for 6 h at 60°C under nitrogen atmosphere. The reaction was quenched by addition of 2 M HCl and extracted with ethyl acetate. The combined organic layer was washed with brine and dried over anhydrous Na_2SO_4 . The reaction product was acetylated with acetic anhydride in pyridine and then purified by column chromatography (eluent: Hex/EtOAc, 7:3) to yield unreacted **14** (45%) and **15** (30 mg, 51%). $[\alpha]_D^{22} = +8.6$ (c, 1.0%); IR cm^{-1} (film): 3421, 2932, 1764, 1721, 1687, 1609, 1461, 1433, 1365, 1020, 1181, 1053, 896, 825. UV λ_{max} (ϵ): 240 (12300), 285 (5900). HRMS-FAB: calcd for $\text{C}_{31}\text{H}_{39}\text{O}_8$ $[\text{M} + \text{H}]^+$: 539.2645; found 539.2642 m/z . RMN ^1H : Table 4. RMN ^{13}C : Table 5. HMQC and HMBC experiment: Table S6.

General procedure for decarboxylation with lead tetracetate. nor-DTHQs **16** and **17**. A solution of **1** (256 mg, 0.52 mmol) and pyridine (1.3 mL, 16 mmol) in dry toluene (10 mL) was heated at 145 °C for 1 h. Then lead tetraacetate (299 mg, 0.67 mmol) and copper diacetate (104 mg, 0.52 mmol) were added and kept stirred at the same temperature for additional 4.5 h. The cooled mixture was evaporated and redissolved in EtOAc. The organic layer was washed consecutively with 2 M HCl and brine and dried over anhydrous Na₂SO₄. The reaction product was purified by column chromatography to yield **16a–c** (109 mg, 47%, eluent: Hex/EtOAc, 95:5) and **17** (53 mg, 20%, eluent: Hex/EtOAc, 9:1). RMN ¹H: Table S14. RMN ¹³C: Table S15. The mixture **16a–c** was chromatographed over silica gel impregnated with 20% silver nitrate, using Hex/EtOAc, 7:3 as eluent, to yield **16a–c** (63 mg, 47%, eluent:) and **16a** (21 mg. Compound **16a**: [α]_D²² = +10.5 (c, 0.54%); IR cm⁻¹ (film): 3400, 2929, 2849, 1766, 1737, 1720, 1643, 1461, 1440, 1366, 1020, 1181, 1053, 890. UV λ_{\max} (ϵ): 240 (5700), 284 (2100). HRMS-FAB: calcd for C₂₉H₃₅O₄ [M + H]⁺: 447.2535; found 447.2516 *m/z*. RMN ¹H: Table 4. RMN ¹³C: Table 5. Compound **17**: [α]_D²² = +11.3 (578), (c, 0.99%) IR cm⁻¹ (film): 3078, 2935, 2870, 1766, 1724, 1641, 1608, 1432, 1366, 1252, 1020, 1181, 1053, 1013, 893, 826, 736. UV λ_{\max} (ϵ): 240 (11400), 285 (4800). RMN ¹H: Table 4. RMN ¹³C: Table 5.

nor-DTHQ **18**. Starting from **3** (250 mg, 0.51 mmol) and following the above procedure for decarboxylation, the CC of the reaction product over AgNO₃ impregnated silicagel (eluent: Hex/EtOAc, 9:1), yielded **18a** (23 mg, 10%), a 1:1:1 mixture of **18a–c** (64 mg, 28%) and **18c** (25 mg, 11%). Compound **18a**: [α]_D²² = +62.1 (c, 0.40%); IR cm⁻¹ (film): 2930, 1765, 1610, 1450, 1365, 1200, 1180, 1050, 1010, 890, 820, 735. HRMS-FAB: calcd for C₂₉H₃₅O₄ [M + H]⁺: 447.2535; found 447.2563 *m/z*. RMN ¹H: Table 4. RMN ¹³C: Table 5. Compound **18c**: [α]_D²² = +99.7 (c, 0.76%); IR cm⁻¹ (film): 2930, 1765, 1610, 1450, 1365, 1200, 1180, 1050, 1010, 895, 825, 735. HRMS-FAB: calcd for C₂₉H₃₅O₄ [M + H]⁺: 447.2535; found 447.2542 *m/z*. RMN ¹H: Table 4. RMN ¹³C: Table 5.

The mixture **18a–c** was dissolved in toluene and iodine (10 mg) was added and stirred at 95 °C for 3 h. The cooled mixture was evaporated and redissolved in EtOAc. The organic layer was washed consecutively with aq sat sodium thiosulphate (Na₂S₂O₃) and brine and dried over anhydrous Na₂SO₄, to yield **18c** (96%).

Table 4. ¹H-NMR data for compounds **14–21** (δ ppm (*J* in Hz)).

H	14 **	15 **	16a *	17 *	18a *	18c *	19 **	20 *	21a **	21c **
6							6.94 <i>bs</i>			
14	7.39 <i>dd</i> (8.8, 1.3)	7.36 <i>dd</i> (8.6, 1.4)	7.39 <i>dd</i> (8.8, 1.8)	7.39 <i>dd</i> (8.8, 1.8)	7.44 <i>dd</i> (8.8, 1.5)	7.45 <i>d</i> (8.4)	7.47 <i>d</i> (8.6)	7.39 <i>dd</i> (8.4, 1.5)	7.41 <i>dd</i> (8.8, 1.8)	7.41 <i>dd</i> (8.8, 1.8)
15	7.78 <i>d</i> (8.8)	7.78 <i>d</i> (8.6)	7.78 <i>d</i> (8.8)	7.79 <i>d</i> (8.8)	7.79 <i>d</i> (8.8)	7.80 <i>d</i> (8.4)	7.82 <i>d</i> (8.6)	7.78 <i>d</i> (8.4)	7.79 <i>d</i> (8.8)	7.78 <i>d</i> (8.8)
16	7.63 <i>bs</i>	7.60 <i>bs</i>	7.57 <i>bs</i>	7.56 <i>bs</i>	7.61 <i>d</i> (1.5)	7.62 <i>bs</i>	7.65 <i>bs</i>	7.35 <i>bs</i>	7.56 <i>bs</i>	7.56 <i>bs</i>
17	2.04 <i>s</i>	2.22 <i>s</i>	5.02 <i>bs</i> 4.72 <i>bs</i>	4.99 <i>bs</i> 4.71 <i>bs</i>	1.70 <i>s</i>	1.75 <i>s</i>	2.35 <i>s</i>	-	-	-
18	1.12 <i>s</i>	1.20 <i>s</i>	4.72 <i>bs</i> 4.41 <i>bs</i>	1.40 <i>bs</i>	4.79 <i>d</i> (1.5) 4.52 <i>d</i> (1.5)	1.66 <i>s</i>	1.30 <i>d</i> (7.0)	1.43 <i>s</i>	4.80 <i>d</i> (1.5) 4.49 <i>d</i> (1.5)	1.64 <i>s</i>
20	1.00 <i>s</i>	0.70 <i>s</i>	0.53 <i>s</i>	0.69 <i>s</i>	0.84 <i>s</i>	1.19 <i>s</i>	2.23 <i>s</i>	0.73 <i>s</i>	0.56 <i>s</i>	0.86 <i>s</i>
2'	7.21 <i>d</i> (8.3)	7.20 <i>d</i> (8.3)	7.21 <i>d</i> (8.3)	7.22 <i>d</i> (8.4)	7.22 <i>d</i> (8.2)	7.23 <i>d</i> (8.2)	7.22 <i>d</i> (8.2)	7.21 <i>d</i> (8.4)	7.21 <i>d</i> (8.0)	7.20 <i>d</i> (8.0)
3'	7.16 <i>d</i> (8.3)	7.15 <i>d</i> (8.3)	7.16 <i>d</i> (8.3)	7.16 <i>d</i> (8.4)	7.17 <i>d</i> (8.2)	7.17 <i>d</i> (8.2)	7.19 <i>d</i> (8.2)	7.16 <i>d</i> (8.4)	7.16 <i>d</i> (8.0)	7.15 <i>d</i> (8.0)
2 x OAc	2.47 <i>s</i> , 2.44 <i>s</i>	2.47 <i>s</i> , 2.44 <i>s</i>	2.47 <i>s</i> , 2.46 <i>s</i>	2.47 <i>s</i> , 2.46 <i>s</i>	2.47 <i>s</i> , 2.45 <i>s</i>	2.48 <i>s</i> , 2.46 <i>s</i>	2.47 <i>s</i> , 2.46 <i>s</i>	2.47 <i>s</i> , 2.46 <i>s</i>	2.47 <i>s</i> , 2.46 <i>s</i>	2.44 <i>s</i> , 2.42 <i>s</i>
19-OCH ₃	3.64 <i>s</i>	3.68 <i>s</i>	-	-	-	-	-	-	-	-
Others		5.43 <i>bs</i> (OH)		1.94 <i>s</i> (4-OAc)				1.94 <i>s</i> (4-OAc)		

* 200 MHz; ** 400 MHz.

Table 5. ^{13}C -NMR data for compounds 14–21 (δ ppm).

C	14 **	15 **	16a *	17 *	18a *	18c *	19 **	20 *	21a **	21c **
1	34.5	30.4	38.5	37.7	36.9	36.9	27.8	37.7	38.7	37.1
2	18.8	19.9	23.9	19.9	21.3	18.8	20.4	19.6	23.2	19.3
3	34.5	37.2	36.7	37.4	36.9	35.2	30.7	37.1	36.5	34.9
4	46.1	43.9	150.5 [#]	85.9	151.0	135.2 [#]	32.7	85.4	148.8	132.5 [#]
5	48.0	51.8	53.7	55.7	48.7	142.1 [#]	139.9	52.4	49.9	127.2 [#]
6	23.3	27.9	27.7	22.7	30.7	30.8	127.9	23.3	26.5	26.3
7	46.1	53.2	37.5	37.7	36.3	33.9	132.9 [#]	42.1	42.0	42.1
8	208.5	216.1	148.1 [#]	147.7	126.9 [#]	123.0 [#]	135.2 [#]	211.4	212.0	212.5
9	214.7	84.3	51.3	53.9	138.4 [#]	138.2 [#]	134.2	62.5	60.6	59.6
10	52.6	49.2	41.8	40.4	40.7	39.5	133.2	43.2	44.6	42.8
11	39.9	38.8	25.9	23.8	23.4	23.6	31.9	23.3	24.0	24.0
12	30.5	31.3	34.9	34.8	32.5	32.1	36.0	34.9	35.1	32.6
13	140.5	141.6	142.0	141.9	142.0	142.1	141.3	141.2	141.4	141.3
14	128.3	128.3	128.5	128.4	128.3	128.3	128.3	128.3	128.5	128.4
15	122.0	121.7	121.6	121.7	121.7	121.7	121.8	121.8	121.7	121.6
16	120.4	119.9	119.9	119.9	119.5	119.5	119.7	120.1	120.1	119.9
17	29.8	31.5	106.2 ^{&}	107.1	19.8	19.9	20.0	-	-	-
18	27.0	28.2	107.4 ^{&}	19.4	105.9	25.6	23.0	19.4	107.4	19.7
19	177.7	177.8	-	-	-	-	-	-	-	-
20	18.8	14.9	12.3	14.3	18.8	19.0	15.0	14.6	13.1	12.7
1'	144.0	143.9	144.0	144.0	143.9	143.9	143.9	143.9	144.0	143.8
2'	117.1	116.7	116.7	116.7	117.7	117.7	116.8	116.8	116.8	116.6
3'	118.0	117.7	117.7	117.7	116.7	116.7	117.7	117.7	117.7	117.6
4'	144.4	144.3	144.4	144.4	144.4	144.3	144.3	144.3	144.3	144.2
5'	126.3	126.1	126.2	126.2	126.2	126.1	126.2	126.2	126.2	126.0
6'	127.8	127.8	127.8	127.9	127.9	127.9	127.9	127.7	127.8	127.6
OAc (2xCO)	169.5	169.3 169.2	169.4	169.2	169.4	169.4	169.3	169.4	169.4	169.2
OAc (2xCH ₃)	21.1	20.9 21.0	21.0	20.9	21.0	20.9	20.9	21.0	21.0	20.8
19-OCH ₃	51.6	51.3								
4-OAc				22.7 170.2				22.7 170.2		

* 50 MHz; ** 100 MHz. #, & Exchangeable signals within each compound.

Treatment of the mixture **16a–c** with aq HI 57% (following the procedure described above to obtain **3**), yield a 1:1 mixture of **18b** and **18c** (66%) after CC of the reaction product, eluted with Hex/EtOAc 95:5.

nor-DTHQ **19**. The mixture **18b–c** (116 mg, 0.26 mmol) was dissolved in toluene (7 mL) and iodine (44 mg, 0.17 mmol) was added and stirred at 95 °C for 24 h. The cooled mixture was evaporated and redissolved in EtOAc. The organic layer was washed consecutively with aq sat Na₂S₂O₃ and brine and dried over anhydrous Na₂SO₄, to yield a reaction crude that was purified by CC to yield **19** (37 mg, 32%, eluent: Hex/EtOAc, 95:5). $[\alpha]_D^{22} = -1.7$ (c, 0.9%); IR cm⁻¹ (film): 2926, 2855, 1766, 1608, 1461, 1431, 1364, 1201, 1180, 1054, 1007, 894, 823. UV λ_{\max} (ϵ): 241 (15100), 283 (4900). MS (m/z): 444 (M)⁺(10). RMN ¹H: Table 4. RMN ¹³C: Table 5. HMQC experiment: Table S7.

dinor-DTHQs **20** and **21**. Starting from **12** (230 mg, 0.46 mmol) and following the above procedure for decarboxylation, the CC of the reaction product yielded **21a** (7 mg, 3%, eluent: Hex/EtOAc, 95:5), **21a–c** (85 mg, 41%, eluent: Hex/EtOAc, 95:5) and **20** (15 mg, 7%, eluent: Hex/EtOAc, 9:1). Compound **20**: $[\alpha]_D^{22} = -16.5$ (c, 0.96%); IR cm⁻¹ (film): 2940, 1765, 1725, 1710, 1365, 1250, 1200, 1180, 1050, 1010. HRMS-ESI: calcd for C₃₀H₃₆O₇Na [M + Na]⁺: 531.2353; found 531.2346 m/z . RMN ¹H: Table 4. RMN ¹³C: Table 5. Compound **21a**: $[\alpha]_D^{22} = -1.6$ (c, 0.67%); IR cm⁻¹ (film): 2936, 2865, 1765, 1707, 1643, 1608, 1433, 1366, 1202, 1182, 1053, 1009, 895, 827, 735. UV λ_{\max} (ϵ): 240 (8800), 285 (4000). HRMS-FAB:

calcd for $C_{28}H_{33}O_5$ $[M + H]^+$: 449.2328; found 449.2330 m/z . RMN 1H : Table 4. RMN ^{13}C : Table 5.

The mixture **21a–c** (85 mg, 0.17 mmol) was dissolved in toluene and iodine (20 mg) was added and stirred at 95 °C for 3 h. The cooled mixture was evaporated and redissolved in EtOAc. The organic layer was washed consecutively with aq sat $Na_2S_2O_3$ and brine, and dried over anhydrous Na_2SO_4 . CC of the reaction product yielded **21c** (27 mg, 32%, eluent: Hex/EtOAc, 9:1). Compound **21c**: IR cm^{-1} (film): 2935, 1765, 1705, 1600, 1430, 1365, 1200, 1180, 1050, 1005, 900, 825. HRMS-FAB: calcd for $C_{28}H_{33}O_5$ $[M + H]^+$: 449.2328 u; found 449.2342 m/z . RMN 1H : Table 4. RMN ^{13}C : Table 5.

3.2. Biological Evaluation

A colorimetric type of assay using sulforhodamine B (SRB) reaction has been adapted for a quantitative measurement of cell growth and viability, following a previously described method [28]. This assay employs 96 well cell culture microplates of 9 mm diameter. Cell lines are obtained from American Type Culture Collection (ATCC) derived from different human cancer types. Cells are maintained in RPMI 1640 10% Fetal Bovine Serum (FBS), supplemented with 0.1 g/L penicillin and 0.1 g/L streptomycin sulfate and then incubated at 37 °C, 5% CO_2 and 98% humidity. For the experiments, cells were harvested from subconfluent cultures using trypsin and resuspended in fresh medium before plating.

Cells were seeded in 96 well microtiter plates, at 5×10^3 cells per well in aliquots of 195 μL of RPMI medium, and they were allowed to attach to the plate surface by growing in drug free medium for 18 h. Afterward, samples were added in aliquots of 5 μL in a ranging from 10 to 10^{-8} $\mu g/mL$, dissolved in DMSO:EtOH:Phosphate Buffered Saline (PBS) (0.5:0.5:99). After 72 h exposure, the antitumor effect was measured by the SRB methodology: cells were fixed by adding 50 μL of cold 50% (wt/vol) trichloroacetic acid (TCA) and incubating for 60 min at 4 °C. Plates were washed with deionised water and dried; 100 μL of SRB solution (0.4% wt/vol in 1% acetic acid) was added to each microtiter well and incubated for 10 min at room temperature. Unbound SRB was removed by washing with 1% acetic acid. Plates are air-dried and bound stain was solubilized with tris(hydroxymethyl)aminomethane (Tris) buffer. Optical densities (OD) were read on an automated spectrophotometric plate reader at a single wavelength of 490 nm. Data analyses were generated automatically by LIMS implementation. Using control OD values (C), test OD values (T) and time zero OD values (T_0), the drug concentration that causes 50% Growth Inhibition (GI_{50} value) was calculated from the equation: $100 \times [(T - T_0) / (C - T_0)] = 50$. Each value represents the mean from triplicate determinations.

4. Conclusions

In this work, we reported several modifications of the decalin core of DTHQs obtained from the natural labdanic diterpenoid myrceocommunic acid. With the aim to enlarge the structural diversity and the number of DTHQ derivatives, we have carried out certain chemical transformations into the natural bicyclic diterpene core, such as epoxidation, ozonolysis or decarboxylation, taking advantage of the functional groups present on it, that are, the double bond around C-8 and the carboxylic group at C-4. Considering this, we have obtained a collection of novel compounds that included some derivatives rearranged towards different diterpenic skeletons as halimane, norlabdane or secoditerpene analogues.

These chemical approaches illustrate the versatility of the labdane ring and show the complex reactivity of the system. Despite the chemical complexity of some rearrangements, most of the final molecules obtained, were thoroughly characterized and their cytotoxicity tested on common solid tumor cell lines. According to the GI_{50} values obtained from the in vitro evaluation, all the compounds tested maintained their cytotoxicity in the μM level, showing no changes in potency when the double bond in the decalin B-ring was isomerized, but the conservation of the terpenic bicyclic system, either decalin or indane, in these molecules seems to be important. Additionally, oxygenated functions such as the ester group in the A-ring appears to be a main point for the activity of this family

of compounds, without forgetting that its cytotoxicity would also be associated with the hydroquinonic part of the molecule, which is identical in all the compounds. These results lay the foundations for the introduction of further functional changes in the decalin moiety that would make possible to obtain more potent and effective antineoplastic compounds.

Supplementary Materials: The following are available online, Tables S1–S7: Correlations and assignments for compounds **8**, **9a**, **10**, **11**, **14**, **15** and **19**. Figures S1–S28: NMR spectra for compounds **3**, **5–21**.

Author Contributions: Design and synthesis Á.P.H., P.C., M.L.R., J.M.M.d.C., P.A.G. and M.Á.C.; Biological assay A.F.; original draft preparation Á.P.H., P.A.G. and M.Á.C.; writing—review and editing A.S.F., J.M.M.d.C. and M.Á.C.; supervision, project administration and funding acquisition A.S.F. and M.Á.C. All authors have read and agreed to the published version of the manuscript.

Funding: This research was funded by Spanish MINECO (CTQ2015-68175-R, AGL2016-79813-C2-2-R), Junta de Castilla y León (SA076P20) and ISCIII-RICET Network (RD16/00270018) cofinanced by the Fondo Social Europeo of the European Union (Fondos FEDER—EU) and USAL (Financiación GIR). The APC was funded by MDPI.

Data Availability Statement: The data presented in this study are available in this article.

Conflicts of Interest: The authors declare no conflict of interest.

Sample Availability: Samples of most of the compounds prepared are available from the authors.

References

1. Menna, M.; Imperatore, C.; D’Aniello, F.; Aiello, A. Meroterpenes from marine invertebrates: Structures, occurrence and ecological implications. *Mar. Drugs* **2013**, *11*, 1602–1643. [[CrossRef](#)]
2. García, P.A.; Hernández, A.P.; San Feliciano, A.; Castro, M.A. Bioactive prenyl- and terpenyl-quinones/hydroquinones of marine origin. *Mar. Drugs* **2018**, *16*, 292.
3. Sunassee, S.N.; Davies-Coleman, M.T. Cytotoxic and antioxidant marine prenylated quinones and hydroquinones. *Nat. Prod. Rep.* **2012**, *29*, 513–535. [[CrossRef](#)] [[PubMed](#)]
4. Miguel del Corral, J.M.; Gordaliza, M.; Castro, A.; Mahiques, M.M.; San Feliciano, A.; Garcia-Gravalos, M.D. Further antineoplastic terpenylquinones and terpenylhydroquinones. *Bioorg. Med. Chem.* **1998**, *6*, 31–41. [[CrossRef](#)]
5. Molinari, A.; Oliva, A.; Reinoso, P.; Miguel del Corral, J.M.; Castro, M.A.; Gordaliza, M.; Gupta, M.P.; Solis, P.; San Feliciano, A. Cytotoxic-antineoplastic activity of hydroquinone derivatives. *Eur. J. Med. Chem.* **2002**, *37*, 177–182. [[CrossRef](#)]
6. Molinari, A.; Oliva, A.; Ojeda, C.; Escobar, J.; Gallardo, C.; Miguel del Corral, J.M.; Castro, A.; Cuevas, C.; San Feliciano, A. Synthesis, characterisation and cytotoxicity of chloro derivatives of prenylnaphthohydroquinone. *Bioorg. Med. Chem.* **2005**, *13*, 3841–3846. [[CrossRef](#)] [[PubMed](#)]
7. Miguel del Corral, J.M.; Castro, M.A.; Gordaliza, M.; Martin, M.L.; Gualberto, S.A.; Gamito, A.M.; Cuevas, C.; San Feliciano, A. Synthesis and cytotoxicity of new aminoterpenylquinones. *Bioorg. Med. Chem.* **2005**, *13*, 631–644. [[CrossRef](#)] [[PubMed](#)]
8. Castro, M.A.; Miguel del Corral, J.M.; Gordaliza, M.; Garcia, P.A.; Gamito, A.M.; Gualberto, S.A.; Batista, R.; San Feliciano, A. A novel synthetic route to cytotoxic 1,4-anthraquinones from 1,4-benzoquinones. *Synthesis* **2005**, *19*, 3202–3208. [[CrossRef](#)]
9. Molinari, A.; Oliva, A.; Ojeda, C.; Miguel del Corral, J.M.; Castro, M.A.; Mollinedo, F.; San Feliciano, A. Synthesis and evaluation as antitumor agents of 1,4-naphthohydroquinone derivatives conjugated with amino acids and purines. *Arch. Pharm.* **2013**, *346*, 882–890. [[CrossRef](#)]
10. Castro, M.A.; Gamito, A.M.; Tangarife-Castano, V.; Roa-Linares, V.; Miguel del Corral, J.M.; Mesa-Arango, A.C.; Betancur-Galvis, L.; Francesch, A.M.; San Feliciano, A. New 1,4-anthracenedione derivatives with fused heterocyclic rings: Synthesis and biological evaluation. *RSC Adv.* **2015**, *5*, 1244–1261. [[CrossRef](#)]
11. Miguel del Corral, J.M.; Gordaliza, M.; Castro, M.A.; Mahiques, M.M.; Chamorro, P.; Molinari, A.; Garcia-Gravalos, M.D.; Broughton, H.B.; San Feliciano, A. New selective cytotoxic diterpenylquinones and diterpenylhydroquinones. *J. Med. Chem.* **2001**, *44*, 1257–1267. [[CrossRef](#)] [[PubMed](#)]
12. Miguel del Corral, J.M.; Castro, M.A.; Rodriguez, M.L.; Chamorro, P.; Cuevas, C.; San Feliciano, A. New cytotoxic diterpenyl-naphthohydroquinone derivatives obtained from a natural diterpenoid. *Bioorg. Med. Chem.* **2007**, *15*, 5760–5774. [[CrossRef](#)] [[PubMed](#)]
13. Castro, M.A.; Miguel del Corral, J.M.; Rodriguez, M.L.; San Feliciano, A. An easy route to pentacyclic terpenylquinones. *Tetrahedron Lett.* **2012**, *53*, 519–521. [[CrossRef](#)]
14. Hernandez, A.P.; Diez, P.; Garcia, P.A.; Miguel del Corral, J.M.; Perez-Andres, M.; Diez, D.; San Feliciano, A.; Fuentes, M.; Castro, M.A. New hybrids derived from podophyllaldehyde and diterpenylhydroquinones with selectivity toward osteosarcoma cells. *ACS Med. Chem. Lett.* **2018**, *9*, 328–333. [[CrossRef](#)]

15. Castro, M.A.; Gamito, A.M.; Tangarife-Castatno, V.; Zapata, B.; Miguel del Corral, J.M.; Mesa-Arango, A.C.; Betancur-Galvis, L.; San Feliciano, A. Synthesis and antifungal activity of terpenyl-1,4-naphthoquinone and 1,4-anthracenedione derivatives. *Eur. J. Med. Chem.* **2013**, *67*, 19–27. [CrossRef]
16. Roa-Linares, V.C.; Miranda-Brand, Y.; Tangarife-Castatno, V.; Ochoa, R.; Garcia, P.A.; Castro, M.A.; Betancur-Galvis, L.; San Feliciano, A. Anti-herpetic, anti-Dengue and antineoplastic activities of simple and heterocycle-fused derivatives of terpenyl-1,4-naphthoquinone and 1,4-anthraquinone. *Molecules* **2019**, *24*, 1279. [CrossRef]
17. Pérez-Pertejo, Y.; Escudero-Martínez, J.M.; Reguera, R.M.; Balaña-Fouce, R.; Garcia, P.A.; Jambrina, P.G.; San Feliciano, A.; Castro, M.A. Antileishmanial activity of terpenylquinones on *Leishmania infantum* and their effects on *Leishmania* topoisomerase IB. *Int. J. Parasitol. Drugs Drug Resist.* **2019**, *11*, 70–79. [CrossRef]
18. El Haib, A.; Benharref, A.; Parrès-Maynadié, S.; Manoury, E.; Daran, J.C.; Urrutigoity, M.; Gouygou, M. Molecular rearrangement of epoxide derived from sesquiterpenes by Lewis acid catalysis. *Tetrahedron Asymmetry* **2010**, *21*, 1272–1277. [CrossRef]
19. Geroge, J.H.; McArdle, M.; Baldwin, J.E.; Adlington, R.M. Biomimetic rearrangements of simplified labdane diterpenoids. *Tetrahedron* **2010**, *66*, 6321–6330. [CrossRef]
20. Mohanraj, S.; Herz, W. Photosensitized oxygenation of labda-8(17),12-diene, labda-8(17), 13-diene, and the biformenes. Synthesis of pumiloxide. *J. Org. Chem.* **1981**, *46*, 1362–1366. [CrossRef]
21. Smith, M.B.; March, J. *March's Advanced Organic Chemistry: Reactions, Mechanism, and Structure*, 6th ed.; John Wiley & Sons: Hoboken, NJ, USA, 2007.
22. Bailey, P.S.; Hwang, H.H.; Chiang, C.-Y. Mechanisms of epoxidation during ozonation of carbon-carbon double bonds. *J. Org. Chem.* **1985**, *50*, 231–234. [CrossRef]
23. Hagiwara, H.; Takeuchi, F.; Nozawa, M.; Hoshi, T.; Suzuki, T. The first total synthesis and determination of the absolute configuration of chapecoderin A, B and C. *Tetrahedron* **2004**, *60*, 1983–1989. [CrossRef]
24. Yang, Z.; Kitano, Y.; Chiba, K.; Shibata, N.; Kurokawa, H.; Doi, Y.; Arakawa, Y.; Tada, M. Synthesis of variously oxidized abietane diterpenes and their antibacterial activities against MRSA and VRE. *Bioorg. Med. Chem.* **2001**, *9*, 347–356. [CrossRef]
25. Fernández-Mateos, A.; Ferrero-Barrueco, O.; De Pascual-Teresa, J.; Rubio-González, R. Synthesis of (-)-4,8 β -dimethyl testolactone from (+)-O-15-methyl isoagathate. *Tetrahedron* **1991**, *47*, 4375–4382. [CrossRef]
26. Marcos, I.S.; Basabe, P.; Laderas, M.; Diez, D.; Jorge, A.; Rodilla, J.M.; Moro, R.F.; Lithgow, A.M.; Barata, I.G.; Urones, J.G. Side-chain migration reactions and ring B aromatization in labdanes: Scope and limitations. Synthesis of isogregenedane type tetrahydronaphthalenic diterpenes. *Tetrahedron* **2003**, *59*, 2333–2343. [CrossRef]
27. National Cancer Institute. Common Cancer Types. Available online: <https://www.cancer.gov/types/common-cancers> (accessed on 8 January 2021).
28. Skehan, P.; Storeng, R.; Scudiero, D.; Monks, A.; McMahon, J.; Vistica, D.; Warren, J.T.; Bokesch, H.; Kenney, S.; Boyd, M.R. New colorimetric cytotoxicity assay for anticancer-drug screening. *J. Natl. Cancer Inst.* **1990**, *82*, 1107–1112. [CrossRef] [PubMed]